Patients' and Healthcare Professionals' Perspectives in Managing Atherosclerotic Cardiovascular Disease: A Survey of Unmet Needs and Perceived Benefits of Treating Systemic Inflammation in Cardiovascular Diseases [0.03%]
动脉粥样硬化性心血管病的患者和医务人员的认知与未满足需求以及治疗系统性炎症的获益：调查报告
Brittany Weber,Delilah McCarty,Carey Robar et al.
Brittany Weber et al.
Few surveys have focused on a patient's journey or healthcare professionals' (HCPs') perspectives in treating inflammation in atherosclerotic cardiovascular disease (ASCVD). Patients with ASCVD (n=200) and HCPs (n=204) completed separate 30...
Magnitude of blood pressure reduction in response to levosimendan infusion independently predicts in-hospital mortality in patients with acute heart failure [0.03%]
左西孟丹滴注降压幅度可独立预测急性心力衰竭患者的住院死亡率
Gianmarco Sarto,Beatrice Simeone,Francesca Sbandi et al.
Gianmarco Sarto et al.
The impact of blood pressure (BP) reduction induced by levosimendan infusion on in-hospital mortality in patients with acute heart failure (AHF) and systolic ventricular dysfunction still needs to be clarified. We conducted a retrospective ...
Integrating Network Pharmacology and In Vitro 3D Cardiac Organoid Model Validation to Investigate the Action Mechanism of Shenfu Xiangshao Decoction on Heart Failure [0.03%]
基于网络药理学和体外心脏类器官模型验证的参附香肖饮治疗心衰作用机制研究
Sijie Yao,Hui Zhang,Min Li et al.
Sijie Yao et al.
Heart failure (HF) represents a significant global public health challenge with profound implications for human health. Shenfu Xiangshao Decoction (SFXSD) is a commonly utilized adjuvant therapy for HF. However, its molecular mechanism rema...
Safety and effectiveness of somatostatin and analogues on chest tube output after coronary artery bypass grafting: A scoping review [0.03%]
生长抑素及其类似物减少冠状动脉旁路移植术后胸管引流的疗效和安全性：系统综述
Caitlin M Gibson,Alisa K Escaño,Katherine D Hobe et al.
Caitlin M Gibson et al.
Somatostatin and analogues may reduce chest tube (CT) output in chylothorax caused by post-coronary artery bypass grafting (CABG). However, data is limited to case reports and series. This scoping review aimed to describe the efficacy and s...
When Phenotyping Is the Intervention: Personlized Treatment of Diffuse Coronary Artery Disease [0.03%]
当表型分析即是干预措施时——弥漫性冠状动脉疾病个性化治疗的策略与展望
Salvatore Giordano,Alberto Morello,Giuseppe Biondi-Zoccai et al.
Salvatore Giordano et al.
Closing the translational gap in cardiovascular artificial intelligence: from drug discovery to evidence synthesis [0.03%]
心血管人工智能的转化差距及如何从药物发现到证据综合予以弥补
Giuseppe Biondi-Zoccai,Giacomo Frati,George W Booz
Giuseppe Biondi-Zoccai
Role of the Gut Microbiome in Modulating Interactions Between β-Lactam Antibiotics and Statins in Coronary Heart Disease [0.03%]
肠道微生物组在调节β-内酰胺类抗生素和他汀类药物在冠心病中相互作用中的作用
Guohui Wang,Yan Luo,Sangcang Song et al.
Guohui Wang et al.
Clinical evidence suggests that the lipid-lowering efficacy of statins may be diminished by concurrent β-lactam administration in patients with coronary heart disease (CHD), yet the mechanisms driving this potential drug-drug interaction, ...
Alanna Arroues,Michael Longo,Mariko Harper
Alanna Arroues
Hypertrophic Cardiomyopathy (HCM) is the most commonly inherited cardiomyopathy worldwide, characterized by left ventricular hypertrophy and hypercontractility. Many cases of HCM are due to pathogenic changes in cardiac sarcomere proteins. ...
Cannabidiol Protects the Heart from Ischemia-Reperfusion Injury Through SIRT-1/PGC-1α Activation and NF-κB Modulation: Experimental Insights [0.03%]
大麻二酚通过SIRT-1/PGC-1α激活和NF-κB调节保护心脏免受缺血再灌注损伤：实验见解
Fatih Aksoy,Mehtap Savran,Dincer Uysal et al.
Fatih Aksoy et al.
Myocardial ischemia-reperfusion (I/R) injury remains a major cause of acute cardiac dysfunction and is characterized by oxidative stress, inflammation, and apoptosis. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, has been reported...
Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives [0.03%]
PCSK9抑制剂治疗Lp(a)相关动脉粥样硬化的疗效：证据与展望
Xinyan Li,Zhongsu Wang,Juan Liang et al.
Xinyan Li et al.
Lipoprotein(a) [Lp(a)] is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD) that drives a significant residual risk through pro-atherogenic, pro-inflammatory, and prothrombotic pathways. How...